Get the Stockscreener App
111.12
2.33%
2.53
After Hours:
111.60
0.48
+0.43%
Insmed Inc stock is traded at $111.12, with a volume of 4.13M.
It is up +2.33% in the last 24 hours and down -12.25% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$108.59
Open:
$107.76
24h Volume:
4.13M
Relative Volume:
1.68
Market Cap:
$24.27B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-19.35
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
-5.69%
1M Performance:
-12.25%
6M Performance:
-31.59%
1Y Performance:
-27.28%
1-Day Range:
$105.68
$111.54
1-Week Range:
$105.68
$119.32
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
111.12 | 25.73B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed | 10/1/26 - ktnv.com
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
3 AI Healthcare Stocks With At Least 8% Revenue Growth - Simply Wall Street
Insmed Price Target Cut to $207.00/Share From $237.00 by Barclays - Moomoo
EMBARC and Insmed plan study to evaluate brensocatib in bronchiectasis - scanx.trade
Net income before discontinued operations of Insmed Incorporated – HAN:IM8N - TradingView
Insmed Incorporated (INSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed Incorporated (INSM) stock price, news, quote and history - uk.finance.yahoo.com
Insmed shares deliver 41.43% annualized return over five years - scanx.trade
Insmed TPIP shows sustained improvement in PAH study - scanx.trade
BMO Capital initiates coverage on Insmed with Outperform rating - scanx.trade
Insmed 15-year return: $1,000 investment grows to $27,361 - scanx.trade
$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today - Benzinga
3 Healthcare Stocks Showing Why the Sector Still Has Momentum - MarketBeat
Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients? - Yahoo Finance
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Why Insmed (INSM) Stock Is Down Today - Quiver Quantitative
2 New Jersey companies named top places to work for 2026. Here's where - Asbury Park Press
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target - Investing.com
Goldman Sachs Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $188 - moomoo.com
Insmed Incorporated (INSM) latest stock news and headlines - Yahoo Finance UK
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
Insmed stock price target maintained at $195 by Mizuho on FDA review - Investing.com Canada
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? - Yahoo Finance
FDA priority review for Insmed's Arikayce sNDA - thepharmaletter.com
Insmed Says FDA Grants Priority Review to Arikayce Supplemental Filing for MAC Lung Disease - Yahoo Finance
Why is Insmed stock climbing today? By Investing.com - Investing.com Canada
Insmed stock rises on FDA priority review for Arikayce By Investing.com - Investing.com Canada
FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 - TradingView
Insmed receives FDA priority review for ARIKAYCE - grafa.com
FDA grants priority review for Insmed’s ARIKAYCE lung disease drug By Investing.com - Investing.com Canada
INSM Looks 44.7% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease - Pluang
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - Insmed Incorporated Investor Relations
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027 - TradingView
A lung-disease drug may reach patients earlier. Insmed gets FDA priority review. - Stock Titan
Insmed stock slips after strong earnings surprise and rich valuation debate - AD HOC NEWS
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Insmed (INSM) Fully Priced After Its 296% Revenue Surge? - webull.com
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out - Yahoo Finance
Insmed Expands Community Impact During Fifth Annual Global Day of Good - PR Newswire
1INSM.MI Interactive Stock Chart | INSMED INC Stock - Yahoo Finance
INSMED Inc Director Brennan David R Sells 25,000 Shares at $124 Each on September 9, 2026 - Kalkine Media
Insmed(INSM.US) Director Sells US$3.1 Million in Common Stock - Moomoo
Insmed Director Sold Shares Worth Over $3.1M - TradingView
Insmed (INSM) director sells 25,000 shares in open-market deal - Stock Titan
Insmed (NASDAQ: INSM) director lines up 25,000-share sale - Stock Titan
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake - Yahoo Finance
Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance? - webull.com
Insmed Incorporated at Cantor Global Healthcare Conference Transcript - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):